CRIS - Curis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0900
-0.0300 (-1.42%)
At close: 4:00PM EDT

2.0900 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close2.1200
Open2.1200
Bid1.9500 x 800
Ask2.0800 x 3000
Day's Range2.0788 - 2.1500
52 Week Range0.6000 - 2.9000
Volume40,355
Avg. Volume190,684
Market Cap69.394M
Beta (3Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?

    If you want to know who really controls Curis, Inc. (NASDAQ:CRIS), then you'll have to look at the makeup of its share...

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 Curis Inc Earnings Call

  • Associated Press

    Curis: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted to extinguish debt, came to 19 cents per share. The drug developer posted revenue of $2.1 million in ...

  • Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop
    Simply Wall St.

    Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop

    It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 40% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the la...

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

    Q4 2018 Curis Inc Earnings Call

  • Associated Press

    Curis: 4Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 18 cents per share. The drug developer posted revenue of $2.8 million in the period. For the year, the company reported that its loss narrowed ...

  • Benzinga

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Benzinga

    What's Driving The Rally In Microcap Biotech Curis?

    Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...

  • Biotech News: Why Curis Stock Is Soaring Today
    InvestorPlace

    Biotech News: Why Curis Stock Is Soaring Today

    A recent bit of biotech news involving Curis has CRIS stock flying high on Monday.Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million.According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then able to collect additional payments of up to $70.70 million from the company. However, Erivedge must reach certain milestones for CRIS to receive these payments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe biotech news also includes Curis already making good use of the money from the deal. It notes that it used a portion of the cash from the deal to pay off some of its debts. It is also using the remaining $30 million from the upfront payment to funds its operations."We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," James Dentzer, President and CEO of Curis, said in a statement. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." * 7 Marijuana Stocks to Play the CBD Trend Erivedge is a drug from Curis that is used to treat patients suffering from Hedgehog signaling due to genetic mutations. The drug does this by targeting a protein called Smoothened.CRIS stock was up 31% as of Monday morning and is up 74% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Curis Stock Is Soaring Today appeared first on InvestorPlace.

  • Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
    GuruFocus.com

    First Eagle Investment Sells Stake in Curis Inc. at Steep Loss

    First Eagle Investment (Trades, Portfolio) Management axed 90.99% of its stake in Curis Inc. (CRIS) on Dec. 31 as the stock hovered near all-time low prices, the New York-based firm disclosed Wednesday. Warning! GuruFocus has detected 3 Warning Signs with CRIS.

  • Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • Top 3 Healthcare Penny Stocks for 2018
    Investopedia

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in the final quarter of 2018.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

    Q3 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Curis: 3Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Curis (CRIS) Shares March Higher, Can It Continue?
    Zacks

    Curis (CRIS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).

  • Simply Wall St.

    Who Are The Top Investors In Curis Inc (NASDAQ:CRIS)?

    Every investor in Curis Inc (NASDAQ:CRIS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...